Literature DB >> 21806398

Economic evaluations of rotavirus immunization for developing countries: a review of the literature.

Hong-Anh T Tu1, Herman J Woerdenbag, Sumit Kane, Mark H Rozenbaum, Shu Chuen Li, Maarten J Postma.   

Abstract

Diarrhea is a leading cause of mortality for children under 5 years of age, and rotavirus is identified as the main cause of severe diarrhea worldwide. Since 2006, two rotavirus vaccines, Rotarix and Rotateq, have been available in the market. These vaccines have proved to have high efficacy in developed countries. Clinical trials are being undertaken in Asia and Africa, and early clinical results found that the vaccine significantly reduces severe diarrhea episodes due to rotavirus (48.3% for Asia and 30.2% for Africa). The WHO recommended that rotavirus immunization be included in all national immunization programs. Based on WHO's recommendations, the Global Alliance for Vaccines and Immunization decided to provide financial support for rotavirus immunization in the developing world. In this article, we attempted to ascertain the cost-effectiveness of universal rotavirus immunization in developing countries. After an extensive literature search, we identified and evaluated 15 cost-effectiveness studies conducted in the developing world. The results from these studies showed that rotavirus immunization is a cost-effective strategy and one of the best interventions to prevent rotavirus-related diarrheal disease. However, rotavirus vaccines are expensive and the vaccine price appears to be the most challenging and crucial factor for decision-makers regarding whether to introduce this vaccine into developing countries' immunization schedules. All the studies concluded that rotavirus immunization is cost effective but may not be affordable for the developing world at present. Developing countries will definitely rely on financial support from international organizations to introduce rotavirus vaccination. It is recommended that more research on cost-effective rotavirus immunization with updated data be conducted and new rotavirus vaccine candidates be developed at a cheaper price to speed up the introduction of rotavirus immunization to the developing world.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21806398     DOI: 10.1586/erv.11.65

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  13 in total

Review 1.  Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries.

Authors:  Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

Review 2.  Economics and financing of vaccines for diarrheal diseases.

Authors:  Sarah M Bartsch; Bruce Y Lee
Journal:  Hum Vaccin Immunother       Date:  2014-04-22       Impact factor: 3.452

3.  The Potential Cost Effectiveness of Different Dengue Vaccination Programmes in Malaysia: A Value-Based Pricing Assessment Using Dynamic Transmission Mathematical Modelling.

Authors:  Asrul Akmal Shafie; Hui Yee Yeo; Laurent Coudeville; Lucas Steinberg; Balvinder Singh Gill; Rohani Jahis
Journal:  Pharmacoeconomics       Date:  2017-05       Impact factor: 4.981

4.  Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines.

Authors:  A T Newall; M Jit; R Hutubessy
Journal:  Pharmacoeconomics       Date:  2014-06       Impact factor: 4.981

Review 5.  A critical literature review of health economic evaluations of rotavirus vaccination.

Authors:  Samuel Aballéa; Aurélie Millier; Sibilia Quilici; Stuart Caroll; Stavros Petrou; Mondher Toumi
Journal:  Hum Vaccin Immunother       Date:  2013-04-09       Impact factor: 3.452

6.  The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections.

Authors:  Manuela Zlamy; Sabine Kofler; Dorothea Orth; Reinhard Würzner; Peter Heinz-Erian; Andrea Streng; Martina Prelog
Journal:  BMC Infect Dis       Date:  2013-03-01       Impact factor: 3.090

Review 7.  Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world.

Authors:  Maarten J Postma; Mark Jit; Mark H Rozenbaum; Baudouin Standaert; Hong-Anh Tu; Raymond C W Hutubessy
Journal:  BMC Med       Date:  2011-07-08       Impact factor: 8.775

8.  Effect of pH on anti-rotavirus activity by comestible juices and proanthocyanidins in a cell-free assay system.

Authors:  Steven M Lipson; Fatma S Ozen; Laina Karthikeyan; Ronald E Gordon
Journal:  Food Environ Virol       Date:  2012-09-12       Impact factor: 4.034

9.  Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option.

Authors:  Shuhui Cui; Ruoyan Gai Tobe; Xiuting Mo; Xiaoyan Liu; Lingzhong Xu; Shixue Li
Journal:  BMC Infect Dis       Date:  2016-11-15       Impact factor: 3.090

10.  An evaluation of the inhibitory effects against rotavirus infection of edible plant extracts.

Authors:  Karen Knipping; Johan Garssen; Belinda van't Land
Journal:  Virol J       Date:  2012-07-26       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.